QLT Announces Appeal Court Decision on Massachusetts Eye and Ear Infirmary Litigation

    Court of Appeals Finds Against QLT and Upholds District Court Decision

    VANCOUVER, Jan. 12 /CNW/ - QLT Inc. (NASDAQ:   QLTI; TSX: QLT) announced
that the United States Court of Appeals for the First Circuit (the "Court of
Appeals") today affirmed the judgment of the United States District Court for
the District of Massachusetts (the "District Court") in the lawsuit brought
against QLT by Massachusetts Eye and Ear Infirmary ("MEEI") in connection with
events related to U.S. patent No. 5,798,349 (the "'349 patent") and certain of
MEEI's research results related to QLT's Visudyne(R). The Court of Appeals
upheld the liability and damages aspects of the 2007 judgment of the District
Court in which QLT was found liable under Massachusetts state law for unfair
trade practices and ordered to pay to MEEI damages equal to 3.01% on past,
present and future worldwide net sales of Visudyne(R) plus interest and
certain legal fees.
    The decision of the District Court had included an award to MEEI of legal
fees in an amount of $14.1 million, to which was applied a reduction of $3
million previously agreed to by MEEI. The Court of Appeals ordered that the
amount of legal fees payable by QLT be remanded to the District Court for
further consideration. QLT is currently reviewing the decision of the Court of
Appeals with its legal counsel and considering its options for further
appellate review.
    Unless the decision is altered on further review, based on net sales of
Visudyne(R) through December 31, 2008 of approximately $2.6 billion, QLT
estimates that the amount of damages and interest that QLT is required to pay
MEEI is approximately US$113.2 million. The amount of legal fees and
post-judgment interest on those legal fees is yet to be determined. In
addition, Massachusetts General Hospital has made a claim to QLT for increased
payments based on the amounts QLT must pay to MEEI, a claim that QLT is
disputing but that has not been resolved. Massachusetts General Hospital may
commence litigation against QLT at any time.
    As of September 30 2008, QLT had cash, short term investments and
restricted cash totaling US$279.9 million. That amount included restricted
cash of approximately US$124.0 million that is being used as security for the
appeal bond that was posted in connection with the appeal in the MEEI
litigation decided by the Court of Appeals. Subject to further review, QLT
expects that the current amount of the damages award will initially be paid
out to MEEI from QLT's restricted cash used to secure the appeal bond. Amounts
owing under the District Court decision by QLT to MEEI on future quarterly
sales of Visudyne will be recorded and paid as they are due.
    As a result of the Court's decision today QLT will be mailing to
shareholders on or about Friday January 16, 2009 a notice prescribed by
Canadian securities laws describing this change in the Company's affairs and
extending the expiry date of the Company's modified "Dutch Auction" tender

    About QLT

    QLT Inc. is a global biopharmaceutical company dedicated to the
discovery, development and commercialization of innovative therapies. Our
research and development efforts are focused on pharmaceutical products in the
field of ophthalmology. In addition, we utilize three unique technology
platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to
create products such as Visudyne(R) and Eligard(R) and future product
opportunities. For more information, visit our web site at www.qltinc.com.

    QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.
    Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a
    registered trademark of Novartis AG.
    Eligard is a registered trademark of Sanofi-aventis.

    QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol
"QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

    Certain statements contained in this press release, which are not
historical facts, are forward-looking statements, as the term is defined in
the Private Securities Litigation Reform Act of 1995. You can identify these
forward-looking statements by QLT's use of words such as, "expect," "plans,"
"estimates," "intends," "believes" and similar expressions that do not relate
to historical matters. Such forward-looking statements are subject to risks
and uncertainties which can cause actual results to differ materially from
those currently anticipated due to a number of factors, which include, but are
not limited to, the ultimate outcome of the litigation against QLT is
uncertain, any further legal review may be unavailable or may result in a
decision even more unfavourable to QLT, and other factors as described in
detail in QLT's Annual Information Form and Annual Report on Form 10-K,
quarterly reports on Form 10-Q and other filings with the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities. If
judgment in the MEEI appeal is not reviewable, or if any such review is
resolved unfavourably to QLT, QLT could be liable for the full amount of the
damages. All forward-looking statements in this press release are made as of
today, based upon information known to QLT as of the date hereof. QLT assumes
no obligation to update or revise any of its forward-looking statements even
if experience or future changes show that indicated results or events will not
be realized.

For further information:

For further information: QLT Inc. Media Contact: Vancouver, Canada,
Karen Peterson, Telephone: (604) 707-7000 or (800) 663-5486, Fax: (604)
707-7001; The Trout Group Investor Relations Contact: New York, USA, Christine
Yang, Telephone: (646) 378-2929; or Marcy Strickler, Telephone: (646)

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890